+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

The Common Technical Document Training Course (ONLINE EVENT: November 24-25, 2025)

  • Training

  • 2 Days
  • Nov 24th 09:00 - Nov 25th 17:00 GMT
  • IPI Academy
  • ID: 6051531
OFF until Oct 20th 2025

This interactive two-day course will provide you with a clear and comprehensive understanding of the regulatory and technical requirements for CMC management of your full and generic application in major markets of the EU and USA. Furthermore, the course examines the requirements for global roll-out of the dossier to ROW regions including LATAM, ASEAN, MENA and CIS territories.

You will increase your ability to manage all aspects of the development of the CMC applications after two days of intensive lectures, group work and discussion sessions, covering everything you need to know about compiling the chemistry and pharmacy section of your generic dossier.

Skills you will gain include:

  • Effective compilation of the Common Technical Document (CTD) and critical review of documentation
  • Quality by design (QbD), critical attributes and developing new product using the CQA pyramid model
  • Compiling and submitting Module 3 (CTD) of your registration dossier
  • Identifying the extent of content expected by EU and US regulators
  • Achieving the quickest turnaround of your submission
  • Managing the pharmaceutical and quality aspects of your developments and registration dossier in Europe and the US
  • Ensuring right-first-time development
  • Meeting the legal framework and guidelines for the CMC/quality part of the dossier and links to GMP

Certification:

  • CPD: 12 hours for your records
  • Certificate of completion

Course Content


Day 1
What is the CTD?
  • Pharmaceutical medicine and documents
  • Introduction to CTD, ICH and eCTD
  • Introduction to data standards relevant to module 3 (incl. EMA SPOR, ISO-IDMP)
The importance of chemistry/manufacturing and controls (CMC)
  • Setting the scene for the module 3 deep-dive
Assessment of biologics and why the CMC section for these products is more extensive
A deep-dive in Module 3 - examining the content of all sections
  • Module 3.2 for the substances (32S)
  • Module 3.2 for the final products (32P)
  • Appendices and regional information in Module 3 (32A and 32R)
  • Additional data for generics in the US (ANDA tables)
  • Process validation deep-dive (S25 + P35)
  • Comparability across batches (ICH Q5E)
  • Quality-by-Design and Quality Target Product Profile (ICH Q8, Q9 and Q10)
  • Analytical method deep-dive (ICH Q2 and beyond)
  • Process analytical technology
  • Pharmaceutical quality system (ICH Q10)
Post-approval maintenance
  • What and why?
  • EU eCTD lifecycle management
  • US eCTD lifecycle management
  • Product lifecycle management (ICH Q12) and established conditions
Day 2
Potential scenario for Module 3
  • EDQM certificate of suitability of monographs of European pharmacopeia (CoS/CEP)
  • Active substance master file (ASMP)
  • US drug master files (DMFs)
Basic principles for eCTD authors (incl. focus on global dossier roll-out)
  • Separating content from contexts
  • Applying the right document granularity
  • Lean and structured authoring
Trends, developments and future outlook
  • Identification of medicinal products (IDMP)
  • FDA Knowledge-Aided-Structured-Assessment and Structured-Application (FDA-KASA)
  • FDA Pharmaceutical quality/Chemistry manufacturing and control (PQ/CMC) data elements
  • EMA Digital Application Dataset Integration (DADI) project
  • Accumulus synergy - global information exchange platform
Summary of Module 3 and what should stand out from the Quality Overall Summary (module 2)